Skip to content
AnalystLens

Medpace Holdings 8-K Report, Financial Results (Feb 9, 2026)

Reports
Earnings & Results·Exhibits & Filings
Filing Date
Filed February 9, 2026
Period End
February 9, 2026
Security
MEDP
In the record · 2016–202610-K1010-Q318-K90

MEDP filed 10 annual reports (10-K), 31 quarterly reports (10-Q) and 90 current reports (8-K) between 2016 and 2026.

  1. Leadership change8-K · Oct ’16Oct ’16
  2. Leadership change8-K · Apr ’19Apr ’19
  3. Material agreement8-K · Mar ’21Mar ’21
  4. Material agreement8-K · Apr ’25Apr ’25

Summary

Summary of the 8-K filed February 9, 2026. Cited figures are marked; the original filing is the authoritative source.

Medpace Holdings, Inc. (Nasdaq: MEDP) reported financial results for the fourth quarter and full year ended December 31, 2025, in a press release furnished as Exhibit 99.1 to this Form 8-K dated February 9, 2026.

Fourth-quarter revenue rose 32.0% to $708.5 milliona, net new business awards were $736.6 million (a net book-to-bill ratio of 1.04x), and GAAP net income was $135.1 million, or $4.67 per diluted share. EBITDA grew 20.0% to $160.2 million, though its margin fell to 22.6% from 24.9% in the prior-year period. For the full year, revenue increased 20.0% to $2,530.2 million, GAAP net income was $451.1 million ($15.28 per diluted share), and EBITDA was $557.7 million.

The company provided 2026 guidance calling for revenue of $2.755 billion to $2.855 billionb, which the filing states represents growth of 8.9% to 12.8%. GAAP net income is forecast at $487.0 million to $511.0 million, diluted EPS at $16.68 to $17.50, and EBITDA at $605.0 million to $635.0 million. The guidance assumes a tax rate of 18.5% to 19.5% and 29.2 million diluted weighted average shares, and excludes any share repurchases after December 31, 2025.

Capital returns were significant in 2025: the company repurchased 2,961,924 shares for $912.9 millionc, with no repurchases in the fourth quarter and $821.7 million remaining under its authorization at year-end. Cash and cash equivalents were $497.0 million at December 31, 2025, and backlog rose 4.3% to $3,027.2 million.

Management will discuss the results on a conference call on February 10, 2026 at 9:00 a.m. ET.

Key Highlights

  1. Q4 2025 revenue of $708.5 million, up 32.0% year over year (31.4% on a constant currency basis).
  2. Q4 2025 net new business awards of $736.6 million, a net book-to-bill ratio of 1.04x; backlog rose 4.3% to $3,027.2 million.
  3. Full-year 2025 revenue of $2,530.2 million, up 20.0%, with GAAP net income of $451.1 million ($15.28 per diluted share).
  4. EBITDA margin compressed to 22.6% in Q4 2025 from 24.9% a year earlier, even as EBITDA rose 20.0% to $160.2 million.
  5. 2026 guidance: revenue of $2.755 billion to $2.855 billion (8.9% to 12.8% growth) and diluted EPS of $16.68 to $17.50.
  6. 2026 EBITDA guidance of $605.0 million to $635.0 million, assuming a tax rate of 18.5% to 19.5%.
  7. Repurchased $912.9 million of stock in 2025 (2,961,924 shares), with $821.7 million left under the authorization and none bought in Q4 2025.

Frequently Asked Questions

  1. How did Medpace perform in the fourth quarter of 2025?

    Revenue rose 32.0% to $708.5 million, and GAAP net income was $135.1 million, or $4.67 per diluted share, versus $3.67 a year earlier. EBITDA increased 20.0% to $160.2 million, but its margin was 22.6% compared with 24.9% in the prior-year quarter. Direct costs, which include reimbursed out-of-pocket expenses, rose to $503.1 million from $358.3 million.

  2. What is the company's business momentum heading into 2026?

    Net new business awards were $736.6 million in Q4 2025, a net book-to-bill ratio of 1.04x, up from $529.7 million a year earlier. Backlog grew 4.3% to $3,027.2 million at December 31, 2025. For the full year, awards totaled $2,646.8 million, a 1.05x book-to-bill ratio.

  3. What does Medpace guide for 2026?

    The company forecasts 2026 revenue of $2.755 billion to $2.855 billion, GAAP net income of $487.0 million to $511.0 million, diluted EPS of $16.68 to $17.50, and EBITDA of $605.0 million to $635.0 million. The guidance assumes 29.2 million diluted weighted average shares, $24.3 million of interest income, and year-end 2025 foreign exchange rates, and it excludes future share repurchases.

  4. How much did Medpace return to shareholders in 2025?

    The company repurchased 2,961,924 shares for a total of $912.9 million in 2025, with none in the fourth quarter. It had $821.7 million remaining under its authorized repurchase program at December 31, 2025. Cash and cash equivalents were $497.0 million at year-end, down from $669.4 million a year earlier.

  5. When and how can investors hear more about these results?

    Medpace will host a conference call at 9:00 a.m. ET on Tuesday, February 10, 2026, with a webcast and replay available in the Investors section of its website at medpace.com. A supplemental slide presentation is also expected to be posted there before the call.